Semaglutide improves symptoms and function in obesity-related heart failure
1. Semaglutide showed significant improvements in KCCQ-CSS score and reduction in body weight compared to placebo. 2. There were fewer serious adverse events in the semaglutide group. Evidence Rating Level: 1 (Excellent) Study Rundown: Obesity and diabetes lead to...